Canadian Diabetes Association issues 2015 interim diabetes guidelines updateIncorporates data on sodium-glucose linked transporter 2 (SGLT2) inhibitors for type 2 diabetes. Prepregnancy diabetes accounts for increasing proportion of congenital anomaliesCanadian study recommends enhanced periconceptional glycemic control to mitigate risk. Insulin pump therapy associated with lower cardiovascular mortality Swedish study shows superior cardiovascular safety compared with multiple daily insulin injections. SGLT2 inhibitors: possible link to an increased risk of ketoacidosis Health Canada begins safety review for “flozin” drug class. Does sitagliptin increase cardiovascular risk in diabetes patients? New study shows no apparent increased risk of major adverse cardiovascular events or hospitalization for heart failure. Metformin bad for fish Mom's diabetes linked with autism Diabetes ups breast cancer risk New report shows pharmacists improve diabetes care Shoppers Drug Mart's latest Sustainable Solutions Report furthers case for expanding pharmacy services. SGLT2 inhibitors for type 2 diabetes What will be the likely therapeutic niche for sodium glucose cotransporter (SGLT2) inhibitors in the management of type 2 diabetes? First Previous 31 32 33 34 35 Next Last